On August 7 2023, Ocular Therapeutix ($NASDAQ:OCUL) released their second quarter earnings results for the fiscal year 2023, which ended on June 30 2023. The total revenue for the quarter was USD 15.2 million, representing a 23.8% increase from Q2 FY2022.
Despite a positive outlook for the company, the stock opened at $4.5 and closed at $4.4, representing a 3.3% drop from the prior closing price of $4.5. The drop in stock price indicated investor concern about the company’s performance in the second quarter of FY2023. The company’s financial performance was mixed, with total revenue increasing compared to last year but net income decreasing. The company attributed the decrease in net income to higher operating expenses and legal and consulting fees.
Despite the mixed financial performance, Ocular Therapeutix CEO Amar Sawhney expressed optimism about the company’s future prospects, citing “positive momentum” in the company’s product pipeline and a “stronger balance sheet” for the future. He also noted that the company had made “significant progress in developing our pipeline of products and forging new partnerships that will help us continue to drive innovation and growth in ocular therapeutics.” Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Ocular Therapeutix. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ocular Therapeutix. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ocular Therapeutix. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Ocular Therapeutix are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Ocular Therapeutix Intrinsic Value Calculator
We at GoodWhale have performed an in-depth analysis of OCULAR THERAPEUTIX‘s financials. Our proprietary Valuation Line showed that the fair value of OCULAR THERAPEUTIX shares is around $14.3. Currently, OCULAR THERAPEUTIX stock is traded at $4.4, which means it is undervalued by 69.3%. We believe that there is a great opportunity for investors to get in on this undervalued stock. More…
Risk Rating Analysis
Star Chart Analysis
The competition between Ocular Therapeutix Inc and its competitors is fierce. Kodiak Sciences Inc, Regeneron Pharmaceuticals Inc, and AbbVie Inc are all vying for a share of the market. Ocular Therapeutix Inc has a strong product lineup and is a market leader, but its competitors are not far behind.
– Kodiak Sciences Inc ($NASDAQ:KOD)
Kodiak Sciences Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel therapeutics to treat chronic and high-prevalence retinal diseases. Its product pipeline includes KSI-301, KSI-501, and KSI-601. The company was founded by Victor J. Perlman and Paul A. Cleveland on March 10, 1997 and is headquartered in Palo Alto, CA.
– Regeneron Pharmaceuticals Inc ($NASDAQ:REGN)
Regeneron Pharmaceuticals Inc is a biopharmaceutical company that discovers, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The company has a market cap of $78.78 billion as of 2022 and a return on equity of 28.25%. Regeneron’s products include the blockbuster drugs Eylea and Praluent, which are used to treat age-related macular degeneration and high cholesterol, respectively. The company also has several other products in its pipeline, including a potential treatment for Alzheimer’s disease.
AbbVie Inc is a research-based biopharmaceutical company. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie’s market cap is $255.67B as of 2022 and its ROE is 66.07%. The company has a diversified product portfolio that includes treatments for cancer, hepatitis C, immune disorders, and neurological conditions. AbbVie is committed to discovering and developing new and innovative therapies to improve the lives of patients around the world.
Ocular Therapeutix‘s second quarter earnings results for FY2023 showed revenue of USD 15.2 million, a 23.8% increase from the same period last year; however, their net income was reported to be USD -20.7 million, compared to the prior year of -18.8 million. This indicates a slight decline in profitability from the previous year, but overall strong revenue growth. As a result, investors reacted negatively to the earnings results, as the stock price moved down the same day. Therefore, investors should closely monitor Ocular Therapeutix’s performance going forward to understand if the company can maintain its revenue growth and profitability or if the long-term outlook needs to be adjusted for potential downside.